- freely available
- re-usable
Pharmaceuticals 2012, 5(11), 1236-1264; doi:10.3390/ph5111236
Review
The Biological Role of PI3K Pathway in Lung Cancer
1
Oncology Unit GPP, 3rd Dept of Medicine, Sotiria General Hospital, University of Athens, Athens 11527, Greece
2
Experimental Therapeutics Program, Division of Hematology/Oncology, Tufts Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
* Author to whom correspondence should be addressed.
Received: 27 September 2012; in revised form: 7 November 2012 / Accepted: 14 November 2012 / Published: 20 November 2012
(This article belongs to the Special Issue PI3 Kinase Inhibitors)
Abstract: Lung cancer is the primary cause of cancer-related mortality worldwide and although improvements in treatment have been achieved over the last few years, long-term survival rates for lung cancer patients remain poor. Therefore, there is an imperative need for molecularly targeted agents that will achieve long-term disease control. Numerous downstream molecular pathways, such as EGF/RAS/RAF/MEK/ERK and PI3K/AKT/mTOR are identified as having a key role in the pathogenesis of various forms of human cancer, including lung cancer. PI3K/AKT/mTOR signal pathway is an important intracellular signal transduction pathway with a significant role in cell proliferation, growth, survival, vesicle trafficking, glucose transport, and cytoskeletal organization. Aberrations in many primary and secondary messenger molecules of this pathway, including mutations and amplifications, are accounted for tumor cell proliferation, inhibition of apoptosis, angiogenesis, metastasis and resistance to chemotherapy-radiotherapy. In this review article, we investigate thoroughly the biological role of PI3K pathway in lung cancer and its contribution in the development of future therapeutic strategies.
Keywords: lung cancer; PI3K pathway inhibitors; molecular pathways
Article Statistics
Click here to load and display the download statistics.Cite This Article
MDPI and ACS Style
Sarris, E.G.; Saif, M.W.; Syrigos, K.N. The Biological Role of PI3K Pathway in Lung Cancer. Pharmaceuticals 2012, 5, 1236-1264.
AMA StyleSarris EG, Saif MW, Syrigos KN. The Biological Role of PI3K Pathway in Lung Cancer. Pharmaceuticals. 2012; 5(11):1236-1264.
Chicago/Turabian StyleSarris, Evangelos G.; Saif, Muhammad W.; Syrigos, Kostas N. 2012. "The Biological Role of PI3K Pathway in Lung Cancer." Pharmaceuticals 5, no. 11: 1236-1264.
Pharmaceuticals
EISSN 1424-8247
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert
